Alfonso Berrocal

Alfonso Berrocal

Auto-generated profile, based on publicly available information

Alfonso Berrocal

Hospital General Universitario de Valencia, Valencia, Spain

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MGMaria Gonzalez-Cao
Maria Gonzalez-Cao
CCClara Mayo de Las Casas
Clara Mayo de Las Casas
JOJuana Oramas
Juana Oramas
MBMiguel-Angel Berciano-Guerrero
Miguel-Angel Berciano-Guerrero
LCLuis de la Cruz
Luis de la Cruz
ABAlfonso Berrocal
Alfonso Berrocal
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance. Contrary to expectations, the first published phase 2 randomized study comparing continuous versus intermittent schedule of dabrafenib (BRAFi) plus trametinib (MEKi) demonstrated a detrimental effect of the “on−off” schedule. Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516). The trial did not meet its primary endpoint of progression free survival (PFS) improvement. Our results show that the antitumor activity of the experimental intermittent schedule of vemurafenib plus cobimetinib is not superior to the standard continuous schedule. Detection of BRAF mutation in cell free tumor DNA has prognostic value for survival and its dynamics has an excellent correlation with clinical response, but not with progression. NGS analysis demonstrated de novo mutations in resistant cases.

2 March 2021 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
MMMargarita Majem
Margarita Majem
JMJose Luis Manzano
Jose Luis Manzano
IMIvan Marquez-Rodas
Ivan Marquez-Rodas
KMKarmele Mujika
Karmele Mujika
EMEva Muñoz-Couselo
Eva Muñoz-Couselo
ABA. Berrocal
A. Berrocal
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.

14 August 2020 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
RHRicardo Hitt
Ricardo Hitt
LIL. Iglesias
L. Iglesias
ALAntonio López-Pousa
Antonio López-Pousa
ABA. Berrocal-Jaime
A. Berrocal-Jaime
JGJ. J. Grau
J. J. Grau
T(the Spanish Head and Neck Cancer Cooperative Group (TTCC)
the Spanish Head and Neck Cancer Cooperative Group (TTCC)

28 January 2020 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
MMMargarita Majem
Margarita Majem
MMMaría Martínez-García
María Martínez-García
MMMaría Martínez-García
María Martínez-García
EMEva Muñoz-Couselo
Eva Muñoz-Couselo
DRD. Rodriguez-Abreu
D. Rodriguez-Abreu
JLJose A. Lopez-Martin,
Jose A. Lopez-Martin,
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.

7 November 2017 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
ABA. Berrocal
A. Berrocal
AAAna Arance
Ana Arance
VCVictoria Eugenia Castellón
Victoria Eugenia Castellón
LCLuis De la Cruz-Merino
Luis De la Cruz-Merino
EEEnrique Espinosa
Enrique Espinosa
SAS. M. Algarra
S. M. Algarra
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

15 December 2015 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
ABA. Berrocal
A. Berrocal
AAAna Arance
Ana Arance
EEE. Espinosa
E. Espinosa
ACA. G. Castaño
A. G. Castaño
MCM. G. Cao
M. G. Cao
SAS. M. Algarra
S. M. Algarra
All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.